Smart Stimuli-Responsive Nanocarriers for Targeted and Precision Drug Delivery: Design Principles, Triggering Mechanisms, and Translational Applications in Pharmaceutical Nanotechnology

Min-Jae Park [1*], Ji-Hoon Lee [2], Hye-Rin Choi [3], Dong-Wook Kim [4]
[1] PhD, College of Pharmacy, Seoul National University, Seoul, South Korea
[2] PhD, Department of Nanobiomedical Science, Yonsei University, Seoul, South Korea.
[3] PhD, School of Pharmacy, Sungkyunkwan University, Suwon, South Korea
[4] PhD, Korea Institute of Science and Technology (KIST), Center for Biomaterials, Seoul, South Korea.

* Corresponding Author: **Min-Jae Park**

Article Info

ISSN (online): 3107-393X
Volume: 01
Issue: 04
July- August 2024
Received: 06-05-2024
Accepted: 08-06-2024
Published: 10-07-2024
Page No: 29-36

Abstract
Smart nanocarriers represent a paradigm shift in pharmaceutical nanotechnology, enabling precision drug delivery through stimuli-responsive mechanisms and targeted therapeutic interventions. These intelligent nanosystems respond to endogenous physiological stimuli such as pH gradients, redox potential, enzyme activity, and temperature variations, or exogenous triggers including light, magnetic fields, and ultrasound, facilitating controlled and site-specific drug release. This article comprehensively reviews the design principles, physicochemical characteristics, and targeting strategies of smart nanocarrier platforms, including polymeric micelles, liposomes, dendrimers, mesoporous silica nanoparticles, and hybrid nanosystems. Emphasis is placed on the molecular mechanisms underlying passive and active targeting, stimuli-responsive drug release pathways, and their integration into precision nanomedicine. The therapeutic applications of smart nanocarriers in oncology, inflammatory disorders, infectious diseases, and chronic pathological conditions are critically examined, highlighting their potential to overcome multidrug resistance, reduce systemic toxicity, and enhance therapeutic efficacy. Despite significant advances, clinical translation faces formulation complexity, biological barriers, scalability concerns, and regulatory challenges. Future directions include the development of multi-stimuli-responsive systems, personalized nanomedicine platforms, and next-generation theranostic nanocarriers combining diagnostic and therapeutic functionalities for improved patient outcomes in precision medicine.

DOI:

Keywords: Smart Nanocarriers, Targeted Drug Delivery, Stimuli-Responsive Systems, Precision Nanomedicine, Pharmaceutical Nanotechnology, Controlled Release

1. Introduction

1.1. Evolution of Pharmaceutical Nanotechnology

The convergence of nanotechnology and pharmaceutical sciences has revolutionized drug delivery by addressing fundamental limitations of conventional therapeutic approaches, including poor bioavailability, non-specific biodistribution, systemic toxicity, and suboptimal pharmacokinetics [1, 2]. Smart nanocarriers, defined as nanoscale delivery vehicles capable of responding to specific biological or external stimuli, represent the forefront of precision nanomedicine [3]. These intelligent systems integrate targeting ligands, stimuli-responsive components,

and therapeutic payloads within architecturally designed nanostructures, enabling spatiotemporal control over drug release at pathological sites [4, 5].

1.2. Rationale for Targeted and Stimuli-Responsive Drug Delivery

Traditional drug administration often results in indiscriminate distribution throughout the body, leading to off-target effects, therapeutic inefficacy, and dose-limiting toxicities [6]. Smart nanocarriers address these challenges through dual mechanisms: targeted accumulation at disease sites via passive or active targeting strategies, and controlled drug release triggered by local pathophysiological conditions or external stimuli [7, 8]. This approach maximizes therapeutic concentrations at target tissues while minimizing systemic exposure, particularly critical in chemotherapy, gene therapy, and treatment of chronic inflammatory diseases [9, 10].

1.3. Scope and Objectives

This article provides a comprehensive analysis of smart nanocarrier technologies in targeted drug delivery, focusing on design principles, physicochemical properties, targeting mechanisms, stimuli-responsive release pathways, and therapeutic applications. The translational challenges and future directions for clinical implementation of these intelligent nanosystems are critically evaluated to guide next-generation pharmaceutical nanotechnology development.

2. Smart Nanocarrier Systems in Drug Delivery

2.1. Polymeric Smart Nanocarriers

Polymeric nanocarriers, including micelles, nanogels, polymersomes, and polymeric nanoparticles, offer versatile platforms for stimuli-responsive drug delivery [11]. Amphiphilic block copolymers self-assemble into core-shell structures, encapsulating hydrophobic drugs within the core while maintaining colloidal stability through the hydrophilic corona [12]. pH-sensitive polymers such as poly(β-amino esters), polyacrylic acid derivatives, and histidine-containing copolymers undergo structural transitions in acidic tumor microenvironments or endosomal compartments, triggering drug release [13, 14]. Redox-responsive polymeric systems incorporating disulfide linkages exploit elevated glutathione concentrations in tumor cells for selective intracellular drug liberation [15].

Thermoresponsive polymers, particularly poly(N-isopropylacrylamide) and elastin-like polypeptides, exhibit lower critical solution temperature transitions, enabling temperature-triggered drug release [16]. Enzyme-responsive polymeric nanocarriers degradable by matrix metalloproteinases, cathepsins, or phospholipases provide disease-specific release mechanisms in cancer and inflammatory conditions [17].

2.2. Lipid-Based and Hybrid Nanocarriers

Liposomes, solid lipid nanoparticles, and nanostructured lipid carriers constitute biocompatible lipid-based platforms extensively employed in clinical applications [18]. Thermosensitive liposomes incorporating dipalmitoylphosphatidylcholine release encapsulated drugs at mild hyperthermia temperatures (40-42°C), facilitating combination with localized heating techniques [19]. pH-sensitive liposomes containing fusogenic lipids undergo membrane destabilization in acidic environments, enhancing endosomal escape and cytoplasmic drug delivery [20].

Hybrid nanocarriers combining lipid bilayers with polymeric or inorganic cores synergistically integrate the advantages of multiple material classes [21]. Lipid-polymer hybrid nanoparticles demonstrate improved drug loading, sustained release profiles, and enhanced stability compared to single-component systems [22].

2.3. Inorganic and Bio-Responsive Nanoplatforms

Mesoporous silica nanoparticles provide tunable pore architectures, high surface areas, and chemical modifiability for controlled drug loading and stimuli-responsive release through gatekeeping mechanisms [23]. Gold nanoparticles, magnetic nanoparticles, and carbon-based nanomaterials enable integration of diagnostic imaging, photothermal therapy, and magnetically guided targeting [24, 25]. These inorganic nanocarriers respond to external stimuli including near-infrared light, magnetic fields, and ultrasound, offering remote-controlled drug release capabilities [26].

3. Targeting and Stimuli-Responsive Mechanisms

3.1. Passive and Active Targeting Strategies

Passive targeting exploits the enhanced permeability and retention effect in solid tumors, where defective vasculature and impaired lymphatic drainage promote nanocarrier accumulation [27]. Optimal nanocarrier dimensions (10-200 nm), prolonged circulation times achieved through PEGylation, and surface charge neutrality enhance passive targeting efficiency [28].

Active targeting incorporates recognition ligands—antibodies, peptides, aptamers, small molecules, or carbohydrates—that bind specifically to overexpressed receptors on target cells [29]. Folate, transferrin, and epidermal growth factor receptors serve as prevalent targets in cancer nanomedicine [30]. Dual-targeting strategies combining passive accumulation with active recognition maximize therapeutic specificity and cellular internalization [31].

3.2. Internal Stimuli-Responsive Systems

pH-responsive nanocarriers capitalize on acidic tumor microenvironments (pH 6.5-6.8) and endosomal/lysosomal compartments (pH 5.0-6.0) for selective drug release [32]. Protonation of ionizable groups induces conformational changes, membrane destabilization, or hydrolytic degradation, triggering payload liberation [33].

Redox-responsive systems utilize the 100-1000 fold higher glutathione concentrations in tumor cytoplasm compared to extracellular spaces [34]. Disulfide bonds, selenium-containing linkages, and other redox-sensitive moieties undergo reductive cleavage, facilitating intracellular drug release [35].

Enzyme-responsive nanocarriers incorporate peptide sequences or polymeric substrates specifically cleaved by disease-associated proteases, including matrix metalloproteinases overexpressed in tumor invasion and metastasis [36]. Reactive oxygen species-responsive systems leverage elevated oxidative stress in inflamed and cancerous tissues for selective drug release [37].

3.3. External Stimuli-Responsive Systems

Thermosensitive nanocarriers respond to localized hyperthermia induced by focused ultrasound, radiofrequency ablation, or photothermal agents, enabling spatiotemporal control over drug release [38]. Near-infrared light-responsive systems incorporating photosensitive chromophores or

photothermal nanoparticles provide non-invasive, deep-tissue penetration and precise spatial control [39].

Magnetic field-responsive nanocarriers containing superparamagnetic iron oxide nanoparticles enable guided navigation to target sites and magnetically triggered drug release through localized heating [40]. Ultrasound-responsive systems exploit acoustic cavitation and mechanical stress for on-demand drug liberation [41].

4. Therapeutic Applications

4.1. Cancer and Precision Oncology

Smart nanocarriers have demonstrated substantial therapeutic potential in overcoming multidrug resistance, enhancing tumor penetration, and reducing chemotherapy-associated toxicities [42]. Doxorubicin-loaded pH-sensitive polymeric micelles and liposomes exhibit improved antitumor efficacy with decreased cardiotoxicity compared to free drug formulations [43]. Redox-responsive nanocarriers delivering chemotherapeutics demonstrate enhanced cytoplasmic drug concentrations and apoptotic activity in resistant cancer cell lines [44].

Combination therapy approaches utilizing smart nanocarriers co-delivering chemotherapeutics and gene therapeutics (siRNA, miRNA) or immunomodulatory agents synergistically enhance therapeutic outcomes [45]. Photo-responsive nanocarriers integrating photodynamic therapy with chemotherapy provide multimodal cancer treatment strategies [46].

4.2. Inflammatory, Infectious, and Chronic Diseases

Smart nanocarriers targeting inflammatory sites through recognition of adhesion molecules, selectins, or inflammatory mediators deliver anti-inflammatory drugs with enhanced efficacy in rheumatoid arthritis, inflammatory bowel disease, and atherosclerosis [47]. Enzyme-responsive systems releasing therapeutics in protease-rich inflammatory microenvironments minimize systemic immunosuppression [48].

In infectious diseases, pH-responsive nanocarriers enhance antibiotic delivery to acidic bacterial microenvironments and intracellular compartments harboring pathogens [49]. Antimicrobial peptide-loaded smart nanocarriers demonstrate improved efficacy against biofilm-associated infections [50].

Chronic disease management benefits from sustained-release smart nanocarriers responding to disease biomarkers. Glucose-responsive insulin delivery systems utilizing phenylboronic acid derivatives or glucose oxidase provide closed-loop diabetes management [51].

5. Challenges and Future Perspectives

5.1. Biological and Formulation Challenges

Smart nanocarriers encounter multiple biological barriers limiting clinical translation, including protein corona formation altering targeting specificity, reticuloendothelial system clearance reducing circulation times, and limited tumor penetration due to elevated interstitial fluid pressure [52, 53]. The complexity of tumor microenvironments, including hypoxia, heterogeneous vascularization, and stromal barriers, necessitates sophisticated nanocarrier design incorporating multiple targeting and release mechanisms [54].

Formulation challenges include maintaining colloidal stability during storage, achieving reproducible self-assembly processes, ensuring consistent drug loading efficiencies, and controlling premature drug leakage [55]. Scalable manufacturing processes compatible with Good Manufacturing Practice requirements remain underdeveloped for many smart nanocarrier platforms [56].

5.2 Regulatory and Clinical Translation Barriers

Regulatory pathways for complex nanotechnology-based drug products require comprehensive characterization of physicochemical properties, biological interactions, and long-term safety profiles [57]. The absence of standardized evaluation methodologies for stimuli-responsive behavior and targeting efficiency complicates regulatory submissions [58].

Clinical translation necessitates validation in relevant disease models, establishment of pharmacokinetic-pharmacodynamic relationships, identification of patient selection biomarkers, and demonstration of clinical benefit over existing therapies [59]. Economic considerations, including manufacturing costs and reimbursement structures, influence commercial viability [60].

5.3. Next-Generation Smart Nanocarriers

Future developments focus on multi-stimuli-responsive nanocarriers integrating multiple triggering mechanisms for enhanced spatiotemporal control [61]. Personalized nanomedicine approaches incorporating patient-specific targeting ligands and drug combinations derived from molecular profiling promise improved therapeutic outcomes [62].

Theranostic nanocarriers combining diagnostic imaging with therapeutic delivery enable real-time monitoring of biodistribution, target engagement, and treatment response [63]. Artificial intelligence-guided nanocarrier design and formulation optimization accelerate development timelines and improve predictive capabilities [64].

Biomimetic nanocarriers utilizing cell membranes, exosomes, or protein coronas enhance biocompatibility and immune evasion [65]. Self-amplifying drug release mechanisms triggered by initial therapeutic effects or cascade reactions provide autonomous treatment intensification [66].

6. Conclusion

Smart nanocarriers represent transformative technologies in pharmaceutical nanotechnology, offering unprecedented control over drug delivery through integration of targeting strategies and stimuli-responsive release mechanisms. The diverse array of polymeric, lipid-based, and inorganic nanoplatforms provides versatile tools for precision medicine applications across oncology, inflammatory diseases, and chronic conditions. While significant advances have been achieved in understanding design principles, targeting mechanisms, and therapeutic applications, clinical translation requires addressing formulation complexity, biological barriers, manufacturing scalability, and regulatory challenges. Future directions emphasizing multi-stimuli responsiveness, personalized approaches, theranostic capabilities, and biomimetic designs promise to advance smart nanocarriers from promising experimental platforms to mainstream clinical therapeutics, ultimately improving patient outcomes through precision nanomedicine.



Fig 1: Classification of smart nanocarriers used in targeted drug delivery



Fig 2: Targeting mechanisms and stimuli-responsive drug release pathways



Fig 3: Translational pathway of smart nanocarriers from formulation design to clinical application

Table 1: Types of smart nanocarriers and their physicochemical characteristics

Nanocarrier Type	Size Range (nm)	Drug Loading Mechanism	Stimuli Responsiveness	Key Advantages
Polymeric micelles	10-100	Hydrophobic core encapsulation	pH, redox, temperature, enzymes	High drug loading, tunable properties
Liposomes	50-500	Lipid bilayer encapsulation	pH, temperature, enzymes	Biocompatibility, clinical approval
Dendrimers	1-15	Surface conjugation, interior encapsulation	pH, redox	Monodisperse, multivalent targeting
Mesoporous silica NPs	50-300	Pore loading with gatekeepers	pH, redox, light, enzymes	High loading capacity, controlled release
Magnetic NPs	10-100	Surface conjugation	Magnetic field, temperature	Imaging capability, guided targeting
Gold NPs	1-150	Surface conjugation	Light, temperature	Photothermal properties, imaging
Polymersomes	50-500	Membrane and aqueous core	pH, redox, enzymes	Mechanical stability, dual loading
Nanogels	20-200	Network encapsulation	pH, temperature, glucose	Swelling behavior, sustained release

Table 2: Targeting strategies employed in smart nanocarrier-based systems

Targeting Strategy	Mechanism	Target Examples	Nanocarrier Integration	Clinical Advantages
Passive targeting	Enhanced permeability and retention	Solid tumors, inflamed tissues	Size optimization, PEGylation	Simplified design, reduced off-target effects
Active targeting	Ligand-receptor interaction	Folate receptor, transferrin receptor, HER2	Surface conjugation of antibodies, peptides, aptamers	Enhanced cellular uptake, specificity
Magnetic targeting	External magnetic field guidance	Localized tumors, vascular lesions	Incorporation of magnetic nanoparticles	Concentrated accumulation, imaging
Enzyme targeting	Disease-specific protease activation	Matrix metalloproteinases, cathepsins	Peptide linkers, polymeric substrates	Disease-selective activation, reduced toxicity
pH targeting	Acidic microenvironment exploitation	Tumor extracellular space, endosomes	pH-sensitive polymers, charge-reversal	Enhanced release kinetics, endosomal escape
Dual targeting	Combined passive and active	Multiple tumor markers	Multi-ligand decoration	Maximized tumor accumulation and uptake

Table 3: Therapeutic applications of smart nanocarriers in drug delivery

Disease Category	Specific Applications	Therapeutic Agents	Smart Nanocarrier Advantages	Clinical Outcomes
Solid tumors	Breast, lung, colon, ovarian cancer	Doxorubicin, paclitaxel, cisplatin	Reduced cardiotoxicity, enhanced tumor penetration, MDR reversal	Improved efficacy, reduced systemic toxicity
Hematological malignancies	Leukemia, lymphoma	Cytarabine, daunorubicin	Targeted bone marrow delivery, reduced neurotoxicity	Enhanced therapeutic index
Inflammatory diseases	Rheumatoid arthritis, IBD	Methotrexate, corticosteroids, biologics	Site-specific delivery, reduced immunosuppression	Improved efficacy, fewer side effects
Infectious diseases	Bacterial, fungal, viral infections	Antibiotics, antifungals, antivirals	Enhanced intracellular delivery, biofilm penetration	Reduced dosing frequency, improved efficacy
Diabetes	Type 1 and 2 diabetes	Insulin, GLP-1 agonists	Glucose-responsive release, prolonged action	Improved glycemic control, reduced hypoglycemia
Cardiovascular disease	Atherosclerosis, myocardial infarction	Statins, antiplatelet agents	Plaque-targeted delivery, reduced bleeding risk	Enhanced plaque stabilization, reduced events
Neurodegenerative diseases	Alzheimer's, Parkinson's	Neuroprotective agents	Blood-brain barrier penetration	Enhanced brain bioavailability

Table 4: Advantages, limitations, and clinical challenges of smart nanocarrier technologies

Aspect	Advantages	Limitations	Clinical Challenges	Proposed Solutions
Drug delivery	Enhanced bioavailability, controlled release, targeted accumulation	Complex formulation, stability concerns	Batch-to-batch variability, scale-up difficulties	Process optimization, quality-by-design approaches
Targeting specificity	Active and passive mechanisms, reduced off-target effects	Heterogeneous target expression, biological barriers	Patient selection, biomarker validation	Companion diagnostics, personalized approaches
Toxicity profile	Reduced systemic exposure, minimized side effects	Potential nanocarrier toxicity, immunogenicity	Long-term safety unknown, accumulation concerns	Biodegradable materials, comprehensive toxicology studies
Manufacturing	Versatile design platforms, multiple drug loading options	Labor-intensive, expensive production	GMP compliance, regulatory complexity	Continuous manufacturing, standardized protocols
Clinical translation	Demonstrated preclinical efficacy, multiple approved products	Limited clinical success rate, high development costs	Regulatory uncertainty, reimbursement issues	Clear regulatory pathways, health economics studies
Stimuli responsiveness	Spatiotemporal control, on-demand release	Insufficient stimulus intensity, incomplete release	In vivo validation challenges, monitoring difficulties	Multi-stimuli systems, imaging integration

7. References

1. Mitchell MJ, Billingsley MM, Haley RM, Wechsler ME, Peppas NA, Langer R. Engineering precision nanoparticles for drug delivery. Nat Rev Drug Discov. 2021;20(2):101-124.
2. Shi J, Kantoff PW, Wooster R, Farokhzad OC. Cancer nanomedicine: progress, challenges and opportunities. Nat Rev Cancer. 2017;17(1):20-37.
3. Mura S, Nicolas J, Couvreur P. Stimuli-responsive nanocarriers for drug delivery. Nat Mater. 2013;12(11):991-1003.
4. Wang J, Li Y, Nie G. Multifunctional biomolecule nanostructures for cancer therapy. Nat Rev Mater. 2021;6(9):766-783.
5. Karimi M, Ghasemi A, Sahandi Zangabad P, *et al*. Smart micro/nanoparticles in stimulus-responsive drug/gene delivery systems. Chem Soc Rev. 2016;45(5):1457-1501.
6. Allen TM, Cullis PR. Liposomal drug delivery systems: from concept to clinical applications. Adv Drug Deliv Rev. 2013;65(1):36-48.
7. Danhier F, Feron O, Préat V. To exploit the tumor microenvironment: passive and active tumor targeting of nanocarriers for anti-cancer drug delivery. J Control Release. 2010;148(2):135-146.
8. Peer D, Karp JM, Hong S, Farokhzad OC, Margalit R, Langer R. Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol. 2007;2(12):751-760.
9. Barenholz Y. Doxil - the first FDA-approved nano-drug: lessons learned. J Control Release. 2012;160(2):117-134.
10. Blanco E, Shen H, Ferrari M. Principles of nanoparticle design for overcoming biological barriers to drug delivery. Nat Biotechnol. 2015;33(9):941-951.
11. Cabral H, Miyata K, Osada K, Kataoka K. Block copolymer micelles in nanomedicine applications. Chem Rev. 2018;118(14):6844-6892.
12. Kataoka K, Harada A, Nagasaki Y. Block copolymer micelles for drug delivery: design, characterization and biological significance. Adv Drug Deliv Rev. 2012;64:37-48.
13. Lee ES, Gao Z, Bae YH. Recent progress in tumor pH targeting nanotechnology. J Control Release. 2008;132(3):164-170.
14. Du JZ, Du XJ, Mao CQ, Wang J. Tailor-made dual pH-sensitive polymer-doxorubicin nanoparticles for efficient anticancer drug delivery. J Am Chem Soc. 2011;133(44):17560-17563.
15. Saito G, Swanson JA, Lee KD. Drug delivery strategy utilizing conjugation via reversible disulfide linkages: role and site of cellular reducing activities. Adv Drug Deliv Rev. 2003;55(2):199-215.
16. Schmaljohann D. Thermo- and pH-responsive polymers in drug delivery. Adv Drug Deliv Rev. 2006;58(15):1655-1670.
17. Hu Q, Katti PS, Gu Z. Enzyme-responsive nanomaterials for controlled drug delivery. Nanoscale. 2014;6(21):12273-12286.
18. Bulbake U, Doppalapudi S, Kommineni N, Khan W. Liposomal formulations in clinical use: an updated review. Pharmaceutics. 2017;9(2):12.
19. Needham D, Anyarambhatla G, Kong G, Dewhirst MW. A new temperature-sensitive liposome for use with mild hyperthermia: characterization and testing in a human tumor xenograft model. Cancer Res. 2000;60(5):1197-1201.
20. Simões S, Moreira JN, Fonseca C, Düzgüneş N, de Lima MC. On the formulation of pH-sensitive liposomes with long circulation times. Adv Drug Deliv Rev. 2004;56(7):947-965.
21. Mandal B, Bhattacharjee H, Mittal N, *et al*. Core-shell-type lipid-polymer hybrid nanoparticles as a drug delivery platform. Nanomedicine. 2013;9(4):474-491.
22. Zhang L, Chan JM, Gu FX, *et al*. Self-assembled lipid-polymer hybrid nanoparticles: a robust drug delivery platform. ACS Nano. 2008;2(8):1696-1702.
23. Tang F, Li L, Chen D. Mesoporous silica nanoparticles: synthesis, biocompatibility and drug delivery. Adv Mater. 2012;24(12):1504-1534.
24. Dreaden EC, Alkilany AM, Huang X, Murphy CJ, El-Sayed MA. The golden age: gold nanoparticles for biomedicine. Chem Soc Rev. 2012;41(7):2740-2779.
25. Sun C, Lee JS, Zhang M. Magnetic nanoparticles in MR imaging and drug delivery. Adv Drug Deliv Rev. 2008;60(11):1252-1265.
26. Paris JL, Cabañas MV, Manzano M, Vallet-Regí M. Polymer-grafted mesoporous silica nanoparticles as ultrasound-responsive drug carriers. ACS Nano. 2015;9(11):11023-11033.
27. Maeda H, Wu J, Sawa T, Matsumura Y, Hori K. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Control Release. 2000;65(1-2):271-284.
28. Suk JS, Xu Q, Kim N, Hanes J, Ensign LM. PEGylation as a strategy for improving nanoparticle-based drug and gene delivery. Adv Drug Deliv Rev. 2016;99:28-51.
29. Byrne JD, Betancourt T, Brannon-Peppas L. Active targeting schemes for nanoparticle systems in cancer therapeutics. Adv Drug Deliv Rev. 2008;60(15):1615-1626.
30. Zwicke GL, Mansoori GA, Jeffery CJ. Utilizing the folate receptor for active targeting of cancer nanotherapeutics. Nano Rev. 2012;3:10.
31. Wang J, Mao W, Lock LL, *et al*. The role of micelle size in tumor accumulation, penetration, and treatment. ACS Nano. 2015;9(7):7195-7206.
32. Gao W, Chan JM, Farokhzad OC. pH-Responsive nanoparticles for drug delivery. Mol Pharm. 2010;7(6):1913-1920.
33. Kanamala M, Wilson WR, Yang M, Palmer BD, Wu Z. Mechanisms and biomaterials in pH-responsive tumour targeted drug delivery: a review. Biomaterials. 2016;85:152-167.
34. Cheng R, Feng F, Meng F, Deng C, Feijen J, Zhong Z. Glutathione-responsive nano-vehicles as a promising platform for targeted intracellular drug and gene delivery. J Control Release. 2011;152(1):2-12.
35. Russo A, DeGraff W, Friedman N, Mitchell JB. Selective modulation of glutathione levels in human normal versus tumor cells and subsequent differential response to chemotherapy drugs. Cancer Res. 1986;46(6):2845-2848.
36. Zelzer M, Todd SJ, Hirst AR, McDonald TO, Ulijn RV. Enzyme responsive materials: design strategies and future developments. Biomater Sci. 2013;1(1):11-39.
37. Napoli A, Valentini M, Tirelli N, Müller M, Hubbell JA.

Oxidation-responsive polymeric vesicles. Nat Mater. 2004;3(3):183-189.
38. Ta T, Porter TM. Thermosensitive liposomes for localized delivery and triggered release of chemotherapy. J Control Release. 2013;169(1-2):112-125.
39. Yavuz MS, Cheng Y, Chen J, *et al*. Gold nanocages covered by smart polymers for controlled release with near-infrared light. Nat Mater. 2009;8(12):935-939.
40. Predict A, Bañobre-López M, Teijeiro A, Rivas J. Magnetic nanoparticle-based hyperthermia for cancer treatment. Rep Pract Oncol Radiother. 2013;18(6):397-400.
41. Husseini GA, Pitt WG. Micelles and nanoparticles for ultrasonic drug and gene delivery. Adv Drug Deliv Rev. 2008;60(10):1137-1152.
42. Cho K, Wang X, Nie S, Chen ZG, Shin DM. Therapeutic nanoparticles for drug delivery in cancer. Clin Cancer Res. 2008;14(5):1310-1316.
43. Yoo JW, Chambers E, Mitragotri S. Factors that control the circulation time of nanoparticles in blood: challenges, solutions and future prospects. Curr Pharm Des. 2010;16(21):2298-2307.
44. Cheng R, Meng F, Deng C, Klok HA, Zhong Z. Dual and multi-stimuli responsive polymeric nanoparticles for programmed site-specific drug delivery. Biomaterials. 2013;34(14):3647-3657.
45. Wang AZ, Langer R, Farokhzad OC. Nanoparticle delivery of cancer drugs. Annu Rev Med. 2012;63:185-198.
46. Lucky SS, Soo KC, Zhang Y. Nanoparticles in photodynamic therapy. Chem Rev. 2015;115(4):1990-2042.
47. Fang RH, Kroll AV, Gao W, Zhang L. Cell membrane coating nanotechnology. Adv Mater. 2018;30(23):1706759.
48. Hu Q, Sun W, Wang C, Gu Z. Recent advances of cocktail chemotherapy by combination drug delivery systems. Adv Drug Deliv Rev. 2016;98:19-34.
49. Huh AJ, Kwon YJ. "Nanoantibiotics": a new paradigm for treating infectious diseases using nanomaterials in the antibiotic resistant era. J Control Release. 2011;156(2):128-145.
50. Zasloff M. Antimicrobial peptides of multicellular organisms. Nature. 2002;415(6870):389-395.
51. Veiseh O, Tang BC, Whitehead KA, Anderson DG, Langer R. Managing diabetes with nanomedicine: challenges and opportunities. Nat Rev Drug Discov. 2015;14(1):45-57.
52. Monopoli MP, Åberg C, Salvati A, Dawson KA. Biomolecular coronas provide the biological identity of nanosized materials. Nat Nanotechnol. 2012;7(12):779-786.
53. Owens DE, Peppas NA. Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles. Int J Pharm. 2006;307(1):93-102.
54. Jain RK, Stylianopoulos T. Delivering nanomedicine to solid tumors. Nat Rev Clin Oncol. 2010;7(11):653-664.
55. Bobo D, Robinson KJ, Islam J, Thurecht KJ, Corrie SR. Nanoparticle-based medicines: a review of FDA-approved materials and clinical trials to date. Pharm Res. 2016;33(10):2373-2387.
56. Sainz V, Conniot J, Matos AI, *et al*. Regulatory aspects on nanomedicines. Biochem Biophys Res Commun. 2015;468(3):504-510.
57. Tinkle S, McNeil SE, Mühlebach S, *et al*. Nanomedicines: addressing the scientific and regulatory gap. Ann N Y Acad Sci. 2014;1313:35-56.
58. Weissig V, Pettinger TK, Murdock N. Nanopharmaceuticals (part 1): products on the market. Int J Nanomedicine. 2014;9:4357-4373.
59. Hare JI, Lammers T, Ashford MB, *et al*. Challenges and strategies in anti-cancer nanomedicine development: an industry perspective. Adv Drug Deliv Rev. 2017;108:25-38.
60. Ventola CL. Progress in nanomedicine: approved and investigational nanodrugs. P T. 2017;42(12):742-755.
61. Banerjee A, Qi J, Gogoi R, Wong J, Mitragotri S. Role of nanoparticle size, shape and surface chemistry in oral drug delivery. J Control Release. 2016;238:176-185.
62. Shi J, Votruba AR, Farokhzad OC, Langer R. Nanotechnology in drug delivery and tissue engineering: from discovery to applications. Nano Lett. 2010;10(9):3223-3230.
63. Janib SM, Moses AS, MacKay JA. Imaging and drug delivery using theranostic nanoparticles. Adv Drug Deliv Rev. 2010;62(11):1052-1063.
64. Liu Y, Zhao K, Ren Y, *et al*. Artificial intelligence in nanoparticle design: advances and opportunities. ACS Nano. 2021;15(11):16883-16900.
65. Fang RH, Hu CM, Luk BT, *et al*. Cancer cell membrane-coated nanoparticles for anticancer vaccination and drug delivery. Nano Lett. 2014;14(4):2181-2188.
66. Wang C, Xu L, Liang C, Xiang J, Peng R, Liu Z. Immunological responses triggered by photothermal therapy with carbon nanotubes in combination with anti-CTLA-4 therapy to inhibit cancer metastasis. Adv Mater. 2014;26(48):8154-8162.